Overview of Tercian

Quick Facts

Property	Description
Active ingredient	Cyamemazine maleate
Form	Tablets, Oral Solution, Ampoules (Injectable)
Pharmacological class	Typical Antipsychotic (Conventional Neuroleptic)
General purpose	Stabilization of thought, relief of severe anxiety/agitation
Origin	Synthetic (Phenothiazine derivative), introduced in France

Cyamemazine: What Type of Antipsychotic is Tercian?

Tercian is the trade name for the pharmaceutical substance Cyamemazine, a synthetic psychoactive agent formally classified as a Typical Antipsychotic, also known as a conventional neuroleptic. The active ingredient, Cyamemazine maleate, belongs chemically to the Phenothiazine family of compounds. The Anatomical Therapeutic Chemical (ATC) classification system catalogs Cyamemazine under the Phenothiazines (N05AA06).

Cyamemazine's classification within the neuroleptic group supports its primary therapeutic role in managing severe mental and emotional distress. Though categorized as a first-generation agent, it is characterized by a unique anti-anxiety and sedative profile, distinguishing it from many classical neuroleptics.

Composition and Available Forms of Tercian

The medicine is a single-ingredient product containing the active substance Cyamemazine and is supplied in multiple distinct dosage forms to meet varied therapeutic needs. These forms include oral solid Tablets, a liquid oral Solution, and Ampoules for injectable administration.

The availability across these preparations allows for administration via both the Oral route for ongoing therapy and the Parenteral route (Intramuscular or Intravenous) for rapid intervention. As a derivative of the Phenothiazine structure, the drug’s action is focused solely on the properties of the Cyamemazine molecule.

General Purpose of the Neuroleptic Agent

The general purpose of this neuroleptic agent is to promote mental and emotional stability by stabilizing profoundly disrupted thought patterns and reducing psychological overactivity. Cyamemazine is characterized by significant calming properties, which help to alleviate intense associated symptoms such as severe anxiety and acute agitation. By exerting a balancing effect on key brain messengers, the drug assists in restoring emotional equilibrium.

What side effects are possible with Tercian?

Possible Side Effects and Safety Information

The safety profile of Tercian (Cyamemazine), a phenothiazine neuroleptic, is documented through several regulatory categories, distinguishing between common, expected effects and rare, serious adverse reactions.

Adverse Reaction Classifications

Official documents classify potential effects across multiple System-Organ Classes, including the Nervous System (e.g., sedation, extrapyramidal symptoms), Cardiovascular System (e.g., orthostatic hypotension), and Endocrine System.

Classification	Examples of Officially Documented Reactions
Very Common / Common	Sedation, Drowsiness, Orthostatic Hypotension (low blood pressure upon standing), Anticholinergic effects (dry mouth, constipation, blurred vision).
Rare	Neuroleptic Malignant Syndrome (NMS), Agranulocytosis, Jaundice, Seizures.

Serious Safety Considerations

The regulatory profile explicitly notes rare but severe adverse reactions, such as Neuroleptic Malignant Syndrome (NMS), a potentially fatal reaction, and Agranulocytosis, a severe reduction in white blood cells. Additionally, the label documents the risk of QT interval prolongation, which affects heart rhythm.

Safety statements for specific populations are also included. The use of conventional antipsychotics in older adults with dementia-related psychosis is associated with an increased risk of death and cerebrovascular events. Furthermore, caution is advised in individuals with severe hepatic or renal impairment.

Time- or duration-related safety patterns indicate that effects like sedation are often more pronounced at the start of treatment, while the potential for Tardive Dyskinesia is associated with long-term exposure. Safety constraints prohibit use in states of severe central nervous system depression and in individuals with known blood dyscrasias.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory information for Cyamemazine (Tercian) overdose is focused on recognizing severe manifestations and mandating immediate emergency action due to high-risk systemic effects.

Documented Overdose Manifestations

Feature	Official Regulatory Statement
Documented presentations	Central Nervous System (CNS) depression, including somnolence and a potential progression to coma, alongside severe hypotension and tachycardia.
Physiological systems affected	Cardiovascular system (risk of serious cardiac disorders), Central Nervous System (CNS) function.

Required Emergency Action

Feature	Official Regulatory Statement
When immediate help is required	Immediately inform a doctor or emergency service due to the explicit risk of serious cardiac disorders following ingestion of an excessive dose.
Management context	Symptomatic and supportive treatment is the basis of care, as no specific antidote is known. This requires continuous ECG monitoring to manage potential cardiotoxicity, such as QTc or QRS interval prolongation.

Overdose management involves supporting vital functions and decontamination measures like activated charcoal for recent ingestions. This profile is consistent with the known toxicological properties of conventional neuroleptic agents.

Therapeutic Uses of Tercian

What Tercian Treats: Main Uses and Benefits

Tercian (Cyamemazine) is commonly used to help with symptomatic relief and may assist with maintaining a sense of stability across specific domains of severe psychiatric distress. It is applied in clinical settings marked by heightened patient distress and acute symptom escalation, offering supportive assistance in symptom management. The medication is used for acute and chronic psychotic states and for the symptomatic treatment of anxiety.

The primary therapeutic areas generally include conditions characterized by noticeable thought disturbances like schizophrenia and related psychoses, as well as states involving intense, pathological anxiety and agitation. In specific scenarios, it is considered relevant for temporary assistance in managing challenging co-occurring symptoms of severe mood disturbances, such as bipolar disorder. The core benefit provided is a notable calming effect which assists with managing heightened physiological activity and supports functional stability.

“The medication may be applied in managing intense emotional distress and is considered relevant for assisting with disorganized thought patterns.”

Quick Fact: Supportive Management for Severe Agitation and Anxiety

Symptom Domain	Key Benefit	Clinical Context
Pathological Anxiety	Easing severe emotional tension	Acute crisis intervention
Behavioral Agitation	Assisting in managing aggressive episodes	Supportive symptom management
Psychotic Symptoms	Supporting functional stability	Use in chronic symptomatic phases

Regulatory References

ANSM Product Characteristics Overview

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Tercian — official regulatory information

The eligibility profile for Tercian (cyamemazine) is structured by specific prohibitions and requirements for conditional use, as defined in official regulatory documentation.

Contraindications (Must NOT Use)

Use of this medicine is strictly forbidden for individuals with:

Known hypersensitivity to cyamemazine or any of its excipients.
Severe cardiovascular disorders.
Narrow-angle glaucoma.
Prostatic hypertrophy (or other conditions causing urinary retention).
Myasthenia gravis.

Conditional or Restricted Use (Use with Caution)

Eligibility is restricted or requires caution and close monitoring for the following populations:

Elderly Patients: Use with caution; lower doses are often required, and continuous monitoring is mandatory. Doses above 100 mg/day are generally not recommended.
Organ Impairment: Caution is required for patients with hepatic impairment, renal impairment, or existing cardiac impairment.
Seizure Risk: Caution is required for patients with a history of seizures, as the medicine can lower the seizure threshold.
Low Blood Cell Counts: Patients with a history of low White Blood Cell (WBC) count require frequent monitoring, and the drug must be discontinued if a decline is observed.

Age and Developmental Stage

Children: Use is officially documented for children ages 6 and older for severe behavioral disturbances. Use in children under 6 is not established.
Pregnancy: Classified as conditional use; should only be used if clearly needed. The label notes risks to the newborn (such as withdrawal symptoms) if the medicine is used during the third trimester.
Breastfeeding: Use is generally not recommended; it is advised that the mother should either discontinue the drug or bottle feed.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Tercian (cyamemazine) necessitates careful consideration regarding co-administration with several categories of medicinal products and substances, as documented in official regulatory labeling.

Pharmacodynamic Interactions

Interactions primarily arise from additive effects. Co-administration with other Central Nervous System (CNS) depressants (e.g., sedatives, opioids) results in enhanced sedation and drowsiness. Combination with other medicines possessing anticholinergic properties increases the risk of peripheral effects like dry mouth and urinary retention. Tercian's alpha-adrenolytic properties lead to an additive hypotensive effect when combined with antihypertensive agents.

Pharmacokinetic and Metabolic Interactions

Cyamemazine is subject to metabolism primarily by CYP450 enzymes, specifically CYP2D6 and CYP3A4. The concurrent use of CYP inhibitors (e.g., certain antidepressants or antifungals) may increase cyamemazine plasma concentrations, while CYP inducers may decrease them. Additionally, the absorption of Tercian can be reduced by co-administration with gastrointestinal adsorbents, such as aluminum-containing antacids, often requiring a separation of doses in time.

Contraindicated and Significant Combinations

Official labeling strongly restricts the use of Tercian with alcohol due to dangerous enhancement of CNS depression. Furthermore, combinations with medicines known to significantly and dangerously prolong the QT interval are contraindicated due to the heightened risk of serious cardiotoxicity. The overall structure mandates vigilance for combinations that alter exposure or augment central and cardiovascular effects.

Mechanism of Action

Tercian (cyamemazine) exerts its effect through a complex mechanistic activity pattern focused on the central nervous system. It engages multiple mechanistic domains by acting as an antagonist (blocker) on several key neurotransmitter receptors, leading to the modulation of overactive or dysregulated physiological processes.

Blocking Dopamine D2 and Serotonin 5 -HT2A Receptors

This represents the primary mechanistic focus, where Tercian intervenes in key neural pathways by blocking both the Dopamine D2 and Serotonin 5 -HT2A receptors. This action modulates specific signaling sequences, thereby influencing the activity of pathways associated with heightened sensory and emotional activity, contributing to the resulting shifts in pathway activity.

Impact on H1 and alpha1 Regulatory Systems

Tercian's mechanism also includes the antagonism of Histamine H1 and alpha1-Adrenergic receptors, which influences systems beyond primary dopamine and serotonin pathways. This broader receptor-mediated signaling affects neural and humoral systems, leading to an alteration in activity within targeted pathways and further contributing to the resulting shifts in pathway activity.

Dosage and Administration Information

How to use Tercian (Cyamemazine)

Tercian, which contains the active substance cyamemazine, is a typical antipsychotic medication primarily used for the management of certain psychotic disorders and associated severe anxiety. This medication is available in various forms, including tablets and oral solutions.

Administration and Dosage

Tercian must only be used under the direct supervision of a healthcare professional. The dosage and frequency of administration are highly individualized based on the specific condition being treated, the patient's age (e.g., lower doses for geriatric patients), and their response to treatment. Dosage adjustments should only be made by a physician.

Oral Administration: The tablets or oral solution are typically taken by mouth. Tablets should generally be swallowed whole with water.
Dosing Schedule: For certain indications, the total daily dose may be divided and administered two or three times a day, or, due to the drug's sedative properties, a large portion of the dose may be administered at bedtime to help manage side effects like somnolence.

Important Considerations

Do not stop taking Tercian abruptly without consulting your doctor, as this may lead to withdrawal-like symptoms or a relapse of the underlying condition.
The full therapeutic effect, particularly for chronic conditions like schizophrenia, may take several weeks to become fully apparent. For anxiety, some effects may be noticeable within one week.
It is crucial to inform your prescribing physician of all other medications you are currently taking, including over-the-counter drugs and herbal supplements, to prevent potential drug-drug interactions.

Regular follow-up appointments and monitoring, which may include physical and laboratory tests (e.g., blood cell counts, metabolic panels), are necessary to ensure the medication is working effectively and to monitor for potential side effects.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase 1: Research Focus

Research has evaluated whether it can impact joint function and whether it is associated with a change in pain levels in participants enrolled in studies involving mild-to-moderate osteoarthritis (OA).

Observed changes in swelling were recorded; the drug’s potential as a targeted anti-inflammatory was investigated. No causal conclusions have been established in published literature to date.
Studies explored the biological pathways potentially involved in the drug’s activity.
One study noted that participants were observed for at least 6 weeks; researchers documented the time until any perceived change was noted.

Phase 2: Combination Research

A separate line of inquiry explored the drug when studied alongside a standard NSAID. Most research exploring combination therapy agrees that it warrants further investigation.

The combination was studied to see if it is associated with changes in absorption and bioavailability of the active component. Researchers hypothesized that the combination might alter drug kinetics.
The research assessed the response and experiences of the participants to the combination; it has been noted that participants with severe renal impairment were typically excluded from trials. Information regarding participants not included in the trials remains limited.
Overall, the evidence describes the findings of studies exploring this drug for early-stage OA management. It is not yet clear whether the long-term outcomes differ between the monotherapy and the combination treatment.

Key Studies & References Influence of Renal Function on the Pharmacokinetics and Tolerability of Prothipendyl: A Phase I Open-Label Study

Frequently Asked Questions (FAQ)

Common questions about Tercian (FAQ)

Q: How is Tercian different from other related medications like [other drug name]?

A: Tercian is officially categorized as a typical antipsychotic, belonging to the phenothiazine class. Official product information notes that, compared to other medications in this group, Tercian has a particularly distinctive anti-anxiety and marked sedative profile. Its unique receptor activity pattern contributes to these noticeable calming effects.

Q: Does Tercian interact with common over-the-counter cold medicines?

A: According to regulatory documents, caution is advised regarding co-administration with other medicines classified as Central Nervous System (CNS) depressants, which can include cold and pain relievers. Combining them may enhance side effects like sedation and drowsiness. Official guidance notes the importance of disclosing all over-the-counter products to a healthcare provider.

Q: Can Tercian be taken with over-the-counter pain relievers?

A: Regulatory information advises caution regarding co-administration with other medicines classified as Central Nervous System (CNS) depressants, as this may enhance side effects like sedation and drowsiness. This class of interaction also extends to medications with anticholinergic properties. Official guidance notes the importance of disclosing all over-the-counter products to a healthcare provider.

Q: Is it common to feel jittery when first starting Tercian?

A: Feeling restless, jumpy, or jittery can be a sign of extrapyramidal symptoms (EPS), which are documented adverse reactions for this medication class. Official product information notes that these symptoms may occur, particularly at the start of treatment or when a dose is being adjusted. A healthcare professional can provide information about how these feelings are managed.

Q: Are there any natural supplements that should not be taken with Tercian?

A: Official interaction warnings state that certain herbal supplements can interfere with the way Tercian is metabolized (broken down) in the liver. These supplements may either increase or decrease the amount of the drug in the body, which can alter its expected effects. Official product information advises that a healthcare provider should be consulted regarding all supplements being taken.

Q: Does Tercian cause weight gain for most people?

A: Yes, weight gain is officially documented as an adverse reaction associated with Tercian. It is included in the list of potential metabolic side effects in the regulatory profile. The need for regular weight monitoring is generally described in clinical guidance for this class of medication.

Q: Are headaches a frequent side effect when starting Tercian?

A: Headache is generally not classified as a 'very common' or 'common' adverse reaction for Tercian in official regulatory documents. While the side effect profile is extensive, headaches are not listed among the most frequent initial complaints. Individual patient responses to the medicine can still vary.

Q: What are the major warnings about using Tercian and driving or operating machinery?

A: Regulatory documents include a strict warning stating that Tercian may impair the ability to drive or operate machinery. This risk is due to its sedative properties and potential to cause drowsiness. The warning is especially emphasized early in the course of treatment before an individual knows how they will react.

Q: Are there any specific foods or drinks I should avoid while on Tercian?

A: Official interaction warnings primarily focus on other medications, alcohol, and certain substances (like antacids) that affect absorption. Regulatory documents do not list specific restrictions regarding common foods or non-alcoholic drinks. However, alcohol is strictly forbidden due to the risk of enhanced CNS depression.

Q: How long do the effects of a single dose of Tercian typically last?

A: The official pharmacokinetic data for the active ingredient, cyamemazine, reports an elimination half-life of approximately 10 hours. The half-life describes the time it takes for half of the drug to be cleared from the bloodstream. This data point helps healthcare professionals determine the appropriate dosing schedule.

Q: What is the usual recommended duration of treatment with Tercian?

A: The recommended duration of treatment is highly individualized and determined by the treating physician based on the patient's underlying condition and response. For chronic conditions, such as psychotic disorders, official clinical guidelines often recommend that maintenance therapy continue for extended periods after initial symptoms have stabilized.

Q: What happens if a dose of Tercian is missed?

A: Standard advice for maintenance medications is generally to take the missed dose as soon as it is remembered, unless it is close to the time for the next scheduled dose. Official guidance advises against doubling a dose to compensate for a missed one. Specific guidance on managing a missed dose should come directly from the prescribing professional.

Q: Does Tercian carry a risk of physical dependence or addiction?

A: Tercian is not classified as a drug with a high risk of abuse, dependence, or addiction in official documents. However, abrupt cessation (sudden stopping) of the medication is known to potentially cause withdrawal-like symptoms. For this reason, official guidance notes that discontinuation of the medication should be supervised by a healthcare professional.

Q: Does Tercian have a boxed warning in official documents?

A: While the specific term 'Boxed Warning' is used by certain regulatory bodies, official labels worldwide highlight a critical safety concern regarding this class of medication. This warning states that use in older adults with dementia-related psychosis is associated with an increased risk of death and cerebrovascular events.

Q: Is Tercian a type of antidepressant?

A: No, the official pharmacological classification systems categorize Tercian (cyamemazine) as a Typical Antipsychotic, also known as a conventional neuroleptic. It is not classified as an antidepressant, although it may be used alongside other medications for a patient's overall management plan.

Q: Does Tercian show up on drug screening tests?

A: Tercian's active ingredient, cyamemazine, is a phenothiazine derivative. While it is generally not included in routine, common drug screening panels, it can be detected if a specialized toxicology screen is ordered. For specific testing concerns, information can be sought from the administering laboratory or a healthcare professional.

Q: Is it common to feel less active or motivated while taking Tercian?

A: Reduced activity, apathy, or loss of motivation is a recognized adverse effect that may be associated with the use of this class of medication. This potential side effect is noted in official documentation and can be discussed with a healthcare professional.

How should Tercian be stored and disposed of?

How to Store and Dispose of Tercian (Cyamemazine)

All storage and disposal instructions for Tercian must adhere strictly to official regulatory labeling to ensure product quality and environmental safety.

Storage Requirements

Tercian must be stored at a temperature below 25°C and kept protected from light and moisture. To maintain product integrity, it must remain in the original container and should not be frozen or refrigerated. A critical requirement is to keep the medicine out of the sight and reach of children.

Disposal Instructions

Expired or unused Tercian must be disposed of in accordance with local requirements. Official instructions state that the medicine must not be thrown into wastewater or regular household waste, but should be returned to a pharmacist or a designated pharmaceutical waste collection point.

Tercian